Results 171 to 180 of about 70,663 (209)
Some of the next articles are maybe not open access.
Expert Opinion on Biological Therapy, 2016
A variety of approaches are being pursued to improve the safety and antitumor potency of chimeric antigen receptor (CAR) T-cell therapy. However, most engineering efforts have thus far been focused on its intracellular signaling domain, while its extracellular antigen-binding domain has received less attention.
Yanling, Wu, Shibo, Jiang, Tianlei, Ying
openaire +2 more sources
A variety of approaches are being pursued to improve the safety and antitumor potency of chimeric antigen receptor (CAR) T-cell therapy. However, most engineering efforts have thus far been focused on its intracellular signaling domain, while its extracellular antigen-binding domain has received less attention.
Yanling, Wu, Shibo, Jiang, Tianlei, Ying
openaire +2 more sources
Cancer Immunotherapy with Chimeric Antigen Receptor (CAR) T Cells
Journal of Onco-Nephrology, 2017Chimeric antigen receptor T cell (CAR T) therapy recently won its first U.S. Food and Drug Administration approval for use in the treatment of patients aged 3-25 with relapsed or refractory acute lymphoblastic leukemia. CAR T cell therapy is the first approved gene therapy in the USA, and brings with it a new paradigm in cancer therapeutics.
Dalia Littman, Elizabeth Hexner
openaire +1 more source
Neurotoxic complications of chimeric antigen receptor (CAR) T-cell therapy
Journal of Neurology, Neurosurgery & PsychiatryChimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of haematological malignancies and has demonstrated efficacy in early trials for solid tumours, neurological and rheumatological autoimmune diseases. However, CAR-T is complicated in some patients by neurotoxicity syndromes including immune-effector cell-associated ...
Frederick W Vonberg +5 more
openaire +2 more sources
Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects [PDF]
Frontiers in Cell and Developmental BiologyAlidadi M +6 more
exaly +2 more sources
Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells
2016Plasmid DNA is being used as a pharmaceutical agent in vaccination, as well as a basic substance and starting material in gene and cell therapy, and viral vector production. Since the uncontrolled expression of backbone sequences present in such plasmids and the dissemination of antibiotic resistance genes may have profound detrimental effects, an ...
Michael, Hudecek +9 more
openaire +2 more sources
Chimeric antigen receptor (CAR) T therapy and cognitive functions
Journal of the Neurological Sciences, 2023Brendan Bryan Jen-Wei, Tan +4 more
openaire +2 more sources
Chimeric antigen receptor (CAR)-T cell therapy.
Nihon rinsho. Japanese journal of clinical medicine, 2019Chimeric antigen receptor (CAR)-T cell therapy, where patients' own T cells are engi- neered to express receptor that targets antigen found on the surface of cancer cells, delivers outstanding efficacy to treat hematological malignancies. This personalized medicine has been actively explored by researchers in academia and quickly developed for clinical
Yukimi, Sakoda, Koji, Tamada
openaire +1 more source
Chimeric antigen receptor (CAR) T-cell therapy: an overview for nurses
Nursing StandardChimeric antigen receptor (CAR) T-cell therapy is a relatively new and innovative immunotherapy for haemato-oncological diseases. In the UK, CAR T-cell therapy can be used to treat some patients with relapsed or refractory acute lymphoblastic leukaemia or diffuse large B-cell lymphoma.
Emma, Thoms, Alison, Simons
openaire +2 more sources
Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells
Journal of Visualized ExperimentsEngineered cell therapies utilizing chimeric antigen receptor (CAR)-T cells have achieved remarkable effectiveness in individuals with hematological malignancies and are presently undergoing development for the treatment of diverse solid tumors. So far, the preliminary evaluation of novel CAR-T cell products has predominantly taken place in xenograft ...
Rosa L, Vincent +4 more
openaire +2 more sources
Chimeric Antigen Receptor (CAR) T-Cell Therapy
JAMA Oncology, 2017John M, Pagel, Howard Jack, West
openaire +2 more sources